<DOC>
	<DOCNO>NCT01798134</DOCNO>
	<brief_summary>This non-randomized , prospective , pilot , Multicenter Study Drug-eluting bead transarterial chemoembolization ( DEB-TACE ) use Doxorubicin-Loaded Embozene® Tandem™ Microspheres treat hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Patients confirm diagnosis HCC accord European Association Study Liver ( EASL ) criterion diagnosis , stag accord Barcelona clinic liver cancer ( BCLC ) criteria 2 . Subject competent willing provide write informed consent order participate study 3 . Adults ( male female ) patient ≥ 18 year age 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Child Pugh classification 011 5 . Multidonar single nodular tumor ≥310cm , Patients bilobar disease treat superselectively single session lobes able treat within 35 week . Patient must least one tumor lesion meet follow criterion : Lesion accurately measure least one dimension accord modify Response Evaluation Criteria In Solid Tumors ( mRECIST ) criteria 6 . No invasion major blood vessel ( hepatic portal , hepatic vein ) bile duct Magnetic resonance imaging ( MRI ) Computed Tomography ( CT ) 7 . Proper blood , liver , renal , heart function : testing result within 2 week registry study 8 . No current infection require antibiotic therapy 9 . Not actively cumarin base anticoagulation suffer know bleed disorder 10 . Measurable disease per Response Evaluation Criteria Solid Tumors ( mRECIST ) 11 . Expected survival 6 month 1 . ECOG performance status &gt; 2 ; ChildPugh class C11 , ASA class 5 2 . Bilirubin level &gt; 3 mg/dl 3 . HCC large vessel biliary duct invasion , diffuse HCC extrahepatic spread 4 . Patients follow contraindicated present : The use doxorubicin MRI Hepatic embolization procedure White blood cell ( WBC ) &lt; 3000 cells/mm3 neutrophil &lt; 1500 cells/mm3 Cardiac ejection fraction &lt; 50 percent assess isotopic ventriculography , echocardiography MR Elevated creatinine great equal 2.5 mg/dl Impaired clot test ( platelet count &lt; 5 x 104/mm3 , Prothrombin timeInternational normalize ratio ( PTINR &gt; 2.0 ) aspartate transaminase ( AST ) and/or alanine transaminase ( ALT ) &gt; 5x ULN , great &gt; 250 U/L Known hepatofugal blood flow Arteriovenous shunt Arterioportal shunt Main stem portal vein occlusion ( point 6 inclusion criterion ) 5 . Women pregnant breast feed 6 . Allergy iodinate contrast use angiography 7 . Tumour burden 50 % liver 8 . Patients objective sign active bacterial , viral ( human immunodeficiency virus ( HIV ) ) , fungal infection 9 . Other primary malignancy evidence metastatic disease 10 . Patients previously treat anthracyclines ( doxorubicin ) . 11 . Any comorbid disease condition event , investigator 's judgment , would place patient undue risk would preclude safe use DEBTACE . 12 . Under circumstance patient enrol study already participate another study treatment primary liver cancer . 13 . Under circumstance patient enrol study receive embolotherapy ( include Selective Internal Radiation Therapy ( SIRT ) ) treatment primary liver cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>To show safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>investigational product</keyword>
</DOC>